Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$647.1MCash on Hand
33.7mo Cash Runway
Follow ZBIO by emailGet an email when ZBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ZBIO, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2027-05-27
Obexelimab
IgG4-RD
BLA
64%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
📣 What ZBIO Says Is Next
in 2027 · “Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial to evaluate clinical activity and safety with data anticipated in 2027.”
Company press release, Nov 5, 2026 · SEC filing
fourth quarter of 2026 · “Zenas expects to report data from the Phase 1 trial in the fourth quarter of 2026.”
Company press release, Nov 5, 2026 · SEC filing
this quarter · ““Across our broader pipeline, we remain on track to report topline Phase 2 SunStone data in SLE and initial Phase 1 data for our oral IL-17 inhibitor, ZB021, this quarter.”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Financing Zenas BioPharma is terminating its prior at-the-market offering, under which it sold about $153.2 million of common stock, and filing a new $200,000,000 at-the-market offering through Jefferies as sales agent. The last reported price on November 4, 2026 was $28.46, and Jefferies may receive up to 3.0% commission. Form 424B5 · SEC filing
Nov 6, 2026 ·
Financing Zenas BioPharma sold about $153.2 million of shares under its $200 million at-the-market program from October 2025, leaving about $46.8 million unsold. That prior program is terminated, and a new $200 million prospectus supplement was filed November 6, 2026. Form 8-K · SEC filing
Nov 5, 2026 ·
Earnings Reported Q3 2026 results with $647.1 million in cash, cash equivalents and investments as of September 30, 2026. FDA set a May 27, 2027 PDUFA date for obexelimab in IgG4-RD and the EMA validated its MAA. Phase 2 SunStone SLE topline data are expected in Q4 2026. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 13, 2026 ·
Clinical trial Zenas presented new obexelimab data in IgG4-RD at a symposium: 12-month flare-free probability of 0.93 (adjudicated) or 0.87 (investigator-determined), median rescue glucocorticoid dose of 0 mg, and significantly lower cumulative glucocorticoid toxicity versus placebo at week 52 (p=0.021). Form 8-K · SEC filing · Press release
Sep 11, 2026 ·
Financing Zenas registered for resale up to 7,000,000 common shares held by InnoCare Pharma, acquired under an October 7, 2025 subscription agreement. The company will receive none of the proceeds. Shares closed at $32.29 on September 10, 2026. Form S-3ASR · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 results with $673.9 million in cash, cash equivalents and investments as of June 30, 2026. FDA accepted the obexelimab BLA for IgG4-RD with a PDUFA date of May 27, 2027. Christy Oliger joins the board effective September 1, 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2030 · Phase 3 · Recruiting · A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis Registry primary completion date, not a results date
Jun 2030 · Phase 3 · Recruiting · A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis Registry primary completion date, not a results date
Jun 2026 · Phase 3 · Active Trial · A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) Registry date passed, readout not confirmed
Nov 2025 · Phase 3 · Active Trial · A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease Registry date passed, readout not confirmed
Sep 2026 · Phase 2 · Active Trial · A Study of Obexelimab in Patients With Systemic Lupus Erythematosus Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ZBIO holds $647.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $57.6M/quarter from operations,
an estimated runway of 33.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:24 · Moderate
Cash runway 34 months
ATM program on file since Nov 2026 +15
Shelf registration (S-3ASR, Oct 2025) +10
Company says cash lasts into 2029 -15We estimate that our existing cash, cash equivalents and investments will be sufficient to fund our projected operations and capital expenditure requirements into 2029.10-Q, Nov 2026
Share count 67,817,793 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ZBIO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZBIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.